AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago. These figures are ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in its latest quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill., drugmaker said it logged earnings of $938 ...

AbbVie Inc (ABBV) is reportedly negotiating to buy Gilgamesh Pharmaceuticals, a private company focusing on mental health treatments, for roughly $1 billion. The discussions, highlighted by Bloomberg, ...

NORTH CHICAGO, IL, USA I July 30, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 ...

AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong ...

AbbVie ABBV reported second-quarter revenue of $15.4 billion (6.6% growth) and adjusted diluted earnings per share of $2.97 ...